Key result
Milk-casein peptides lower systolic and diastolic blood pressure in hypertensive rats.
In this study we evaluated the short-term oral antihypertensive effect of several peptide sequences isolated from casein fractions, previously characterized as in vitro angiotensin-converting enzyme-inhibitors, in spontaneously hypertensive rats (SHR). Systolic blood pressure (SBP) and the diastolic blood pressure (DBP) of the rats were measured by the tail cuff method before administration and also 2, 4, 6, 8 and 24 h post-administration. The sequences LVYPFTGPIPN, HLPLP, IAK, YAKPVA and WQVLPNAVPAK showed a clear decrease in SBP and DBP in SHR. HPHPHLSF caused a significant decrease of the DBP in the SHR, but this sequence did not modify the SBP of these animals in a significant manner. KKYNVPQL did not modify SBP in the SHR, and caused a slight, but significant and maintained, decrease in DBP in these animals. SBP and DBP returned to baseline values 24 h post-administration of all peptides. In conclusion, these peptides are bioactive ingredients with potential benefit in the prevention and treatment of hypertension or other associated disorders.
No takes yet. Share an insight, caveat, or question.
Miguel et al. (2010) studied Hypertension. Milk-casein-derived peptides vs. Baseline values was evaluated on Systolic and diastolic blood pressure. Single oral administration of specific milk-casein-derived peptides significantly decreased systolic and diastolic blood pressure in spontaneously hypertensive rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: